回应：阿柏西普用于治疗卡恩斯-塞尔综合征中的色素性视网膜病变？ - Suppr

Response: Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre Syndrome?

作者信息

Leung Vannessa, Wong James, Grigg John R

机构信息

Save Sight Institute Faculty of Medicine and Health, Sydney Eye Hospital, University of Sydney, Macquarie St Sydney, Sydney, NSW, 2000, Australia.

Sydney Eye Hospital, Sydney, Australia.

出版信息

Doc Ophthalmol. 2025 Jun;150(3):199-200. doi: 10.1007/s10633-025-10023-4. Epub 2025 May 20.

DOI:10.1007/s10633-025-10023-4

PMID:40392487

Abstract

摘要

相似文献

Response: Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre Syndrome?

Doc Ophthalmol. 2025 Jun;150(3):199-200. doi: 10.1007/s10633-025-10023-4. Epub 2025 May 20.

Anti-VEGF therapy for proliferative diabetic retinopathy in Kearns-Sayre syndrome.

Doc Ophthalmol. 2025 Feb;150(1):41-46. doi: 10.1007/s10633-024-09999-2. Epub 2024 Dec 27.

Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre syndrome?

Doc Ophthalmol. 2025 Jun;150(3):197-198. doi: 10.1007/s10633-025-10022-5. Epub 2025 May 20.

[Kearns-Sayre syndrome: ophthalmic manifestations].

An Pediatr (Barc). 2015 Jan;82(1):e151-3. doi: 10.1016/j.anpedi.2014.05.012. Epub 2014 Nov 20.

Ophthalmologic school-based screening revealing Kearns-Sayre syndrome: a case report.

Pan Afr Med J. 2022 Mar 18;41:226. doi: 10.11604/pamj.2022.41.226.33085. eCollection 2022.

Anesthetic management of Kearns-Sayre syndrome. Case report.

Rev Esp Anestesiol Reanim (Engl Ed). 2021 Apr;68(4):232-234. doi: 10.1016/j.redar.2020.04.007. Epub 2020 Nov 5.

Kearns-Sayre syndrome presenting with progressive external ophthalmoplegia and third-degree atrioventricular block diagnostic challenge in resource-limited settings: a case report.

J Med Case Rep. 2025 Mar 20;19(1):127. doi: 10.1186/s13256-025-05086-5.

Kearns-Sayre syndrome: a case report and review.

Eur J Ophthalmol. 1992 Jan-Mar;2(1):15-20. doi: 10.1177/112067219200200104.

Kearns-Sayre syndrome: An unusual ophthalmic presentation.

Oman J Ophthalmol. 2012 May;5(2):115-7. doi: 10.4103/0974-620X.99377.

Kearns-Sayre syndrome with a phenocopy of choroideremia instead of pigmentary retinopathy.

Neurology. 1993 Jan;43(1):218-21. doi: 10.1212/wnl.43.1_part_1.218.

本文引用的文献

Anti-VEGF therapy for proliferative diabetic retinopathy in Kearns-Sayre syndrome.

Doc Ophthalmol. 2025 Feb;150(1):41-46. doi: 10.1007/s10633-024-09999-2. Epub 2024 Dec 27.

Effects of Ranibizumab and Aflibercept on Human Müller Cells and Photoreceptors under Stress Conditions.

Int J Mol Sci. 2017 Mar 1;18(3):533. doi: 10.3390/ijms18030533.

Drug-induced mitochondrial dysfunction and cardiotoxicity.

Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1453-67. doi: 10.1152/ajpheart.00554.2015. Epub 2015 Sep 18.

Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.

Acta Ophthalmol. 2015 Dec;93(8):e631-43. doi: 10.1111/aos.12745. Epub 2015 May 14.

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.

Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i11-16. doi: 10.1136/bjophthalmol-2014-305302.

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

J Clin Oncol. 2005 Feb 1;23(4):792-9. doi: 10.1200/JCO.2005.05.098.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Response: Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre Syndrome?

作者信息

Leung Vannessa, Wong James, Grigg John R

机构信息

Save Sight Institute Faculty of Medicine and Health, Sydney Eye Hospital, University of Sydney, Macquarie St Sydney, Sydney, NSW, 2000, Australia.

Sydney Eye Hospital, Sydney, Australia.

出版信息

Doc Ophthalmol. 2025 Jun;150(3):199-200. doi: 10.1007/s10633-025-10023-4. Epub 2025 May 20.

DOI:10.1007/s10633-025-10023-4

PMID:40392487

Abstract

摘要

相似文献

Response: Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre Syndrome?

Doc Ophthalmol. 2025 Jun;150(3):199-200. doi: 10.1007/s10633-025-10023-4. Epub 2025 May 20.

Anti-VEGF therapy for proliferative diabetic retinopathy in Kearns-Sayre syndrome.

Doc Ophthalmol. 2025 Feb;150(1):41-46. doi: 10.1007/s10633-024-09999-2. Epub 2024 Dec 27.

Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre syndrome?

Doc Ophthalmol. 2025 Jun;150(3):197-198. doi: 10.1007/s10633-025-10022-5. Epub 2025 May 20.

[Kearns-Sayre syndrome: ophthalmic manifestations].

An Pediatr (Barc). 2015 Jan;82(1):e151-3. doi: 10.1016/j.anpedi.2014.05.012. Epub 2014 Nov 20.

Ophthalmologic school-based screening revealing Kearns-Sayre syndrome: a case report.

Pan Afr Med J. 2022 Mar 18;41:226. doi: 10.11604/pamj.2022.41.226.33085. eCollection 2022.

Anesthetic management of Kearns-Sayre syndrome. Case report.

Rev Esp Anestesiol Reanim (Engl Ed). 2021 Apr;68(4):232-234. doi: 10.1016/j.redar.2020.04.007. Epub 2020 Nov 5.

Kearns-Sayre syndrome presenting with progressive external ophthalmoplegia and third-degree atrioventricular block diagnostic challenge in resource-limited settings: a case report.

J Med Case Rep. 2025 Mar 20;19(1):127. doi: 10.1186/s13256-025-05086-5.

Kearns-Sayre syndrome: a case report and review.

Eur J Ophthalmol. 1992 Jan-Mar;2(1):15-20. doi: 10.1177/112067219200200104.

Kearns-Sayre syndrome: An unusual ophthalmic presentation.

Oman J Ophthalmol. 2012 May;5(2):115-7. doi: 10.4103/0974-620X.99377.

Kearns-Sayre syndrome with a phenocopy of choroideremia instead of pigmentary retinopathy.

Neurology. 1993 Jan;43(1):218-21. doi: 10.1212/wnl.43.1_part_1.218.

本文引用的文献

Anti-VEGF therapy for proliferative diabetic retinopathy in Kearns-Sayre syndrome.

Doc Ophthalmol. 2025 Feb;150(1):41-46. doi: 10.1007/s10633-024-09999-2. Epub 2024 Dec 27.

Effects of Ranibizumab and Aflibercept on Human Müller Cells and Photoreceptors under Stress Conditions.

Int J Mol Sci. 2017 Mar 1;18(3):533. doi: 10.3390/ijms18030533.

Drug-induced mitochondrial dysfunction and cardiotoxicity.

Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1453-67. doi: 10.1152/ajpheart.00554.2015. Epub 2015 Sep 18.

Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.

Acta Ophthalmol. 2015 Dec;93(8):e631-43. doi: 10.1111/aos.12745. Epub 2015 May 14.

Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.

Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i11-16. doi: 10.1136/bjophthalmol-2014-305302.

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

J Clin Oncol. 2005 Feb 1;23(4):792-9. doi: 10.1200/JCO.2005.05.098.

Response: Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre Syndrome?

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Response: Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre Syndrome?

作者信息

机构信息

出版信息

相似文献

本文引用的文献